Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094324 | 0.93 | CCKBR (0.57) | CCKBRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6097770 | 0.85 | CCKBR (0.49) | CCKBRRAB9ANPC1 | |
| SCHEMBL6098547 | 0.84 | CCKBR (0.48) | CCKBR | |
| SCHEMBL6339248 | 0.82 | CCKBR (0.61) | CCKBRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6094542 | 0.81 | CCKBR (0.58) | CCKBRPDE4D | |
| SCHEMBL6334200 | 0.80 | CCKBR (0.60) | CCKBR | |
| SCHEMBL6334704 | 0.79 | CCKBR (0.61) | CCKBRRAB9ANPC1 | |
| SCHEMBL7115482 | 0.79 | CCKBR (0.51) | CCKBR | |
| SCHEMBL6332196 | 0.76 | CCKBR (0.52) | CCKBR | |
| SCHEMBL6334684 | 0.75 | CCKBR (0.61) | CCKBRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034048-B2 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-04-25 | — | — | US | disclosed |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-09 | — | — | US | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | CCKAR, CCKBR, GRPR | CCKBR 2/4885TTR 3193/4885ALB 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.